Cargando…

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

SIMPLE SUMMARY: Tamoxifen is an important adjuvant endocrine therapy in estrogen receptor (ER)-positive breast cancer patients. It is mainly catalyzed by the enzyme CYP2D6 into the most active metabolite endoxifen. Genetic variation in the CYP2D6 gene influences endoxifen formation and thereby poten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulder, Tessa A. M., de With, Mirjam, del Re, Marzia, Danesi, Romano, Mathijssen, Ron H. J., van Schaik, Ron H. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917604/ https://www.ncbi.nlm.nih.gov/pubmed/33673305 http://dx.doi.org/10.3390/cancers13040771

Ejemplares similares

CYP3A4(∗)22 Genotyping in Clinical Practice: Ready for Implementation?
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
por: Del Re, Marzia, et al.
Publicado: (2010)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
por: Lin, Guigao, et al.
Publicado: (2016)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

Correction: National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
Publicado: (2016)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes
por: van Schaik, Ron H.N.
Publicado: (2008)

Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose
por: Berger, Florine A., et al.
Publicado: (2019)

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
por: Lammers, L A, et al.
Publicado: (2010)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
por: Hussaarts, Koen G.A.M., et al.
Publicado: (2019)

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
por: van Eerden, Ruben A. G., et al.
Publicado: (2023)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
por: Braal, C. Louwrens, et al.
Publicado: (2022)

No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness
por: Koopmans, Anne B., et al.
Publicado: (2018)

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
por: Love, Richard R, et al.
Publicado: (2013)

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
por: Helland, Thomas, et al.
Publicado: (2017)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
por: Sirachainan, Ekaphop, et al.
Publicado: (2012)

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2020)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
por: Prat, A., et al.
Publicado: (2012)

Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial
por: Braal, C. Louwrens, et al.
Publicado: (2022)

Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation
por: Braal, C. Louwrens, et al.
Publicado: (2022)

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
por: Klopp-Schulze, Lena, et al.
Publicado: (2020)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis
por: Lum, Danny W. K., et al.
Publicado: (2013)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis
por: Lu, Junjun, et al.
Publicado: (2017)

The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients
por: Ismail Al-khalil, Wouroud, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ttc4l632ff7ilnkc1kiueqh3q